The BCL6 (B-cell lymphoma 6) transcriptional repressor has emerged as a critical therapeutic target in diffuse large B-cell lymphomas (DLBCL). Although a sequence-specific transcription factor that...
No takes yet. Share an insight, caveat, or question.
Cerchietti et al. (2013) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: